Pernomian Laena, Waigi Emily W, Nguyen Vi, Mohammed Ahmed D, Costa Tiago J, Fontes Milene T, Kubinak Jason L, Aitken Andrew V, Biancardi Vinicia Campana, Gleason Kamryn, Shazly Tarek, Sinclair David A, McCarthy Cameron G, Wang Yunguan, Tan Wenbin, Wenceslau Camilla Ferreira
Department of Cell Biology and Anatomy, Cardiovascular Translational Research Center (L.P., E.W.W., T.J.C., M.T.F., C.G.M., C.F.W.), School of Medicine Columbia, University of South Carolina.
Department of Cell Biology and Anatomy (L.P., E.W.W., V.N., T.J.C., M.T.F., C.G.M., W.T., C.F.W.), School of Medicine Columbia, University of South Carolina.
Circ Res. 2025 Sep 26;137(8):1092-1113. doi: 10.1161/CIRCRESAHA.124.324909. Epub 2025 Sep 3.
Small artery remodeling and endothelial dysfunction are hallmarks of hypertension. Evidence supports a likely causal association between cardiovascular diseases and endothelial-to-mesenchymal transition (EndMT), a cellular transdifferentiation process in which endothelial cells (ECs) partially lose their identity and acquire mesenchymal phenotypes. EC reprogramming represents an innovative strategy in regenerative medicine to prevent deleterious effects induced by cardiovascular diseases.
Using partial reprogramming of ECs, via overexpression of Oct-3/4-Sox-2-Klf-4 (OSK) transcription factors, we aimed to bring ECs back to a youthful phenotype in hypertension. Primary ECs were infected with lentiviral vectors (LVs) containing the specific EC promoter Cdh5 (cadherin-5) and the reporter EGFP (enhanced green fluorescent protein) with empty vector (LV control) or LV with Oct-3/4-Sox-2-Klf-4. Confocal microscopy and Western blotting analysis were used to confirm OSK overexpression. Cellular migration, senescence, and apoptosis were evaluated. Human aortic ECs from normotensive patients and patients with hypertension were analyzed after OSK treatments for eNOS (endothelial nitric oxide synthase), nitric oxide (NO), and genetic profile. Male and female normotensive (BPN/3J or blood pressure normal mouse strain) and hypertensive (BPH/2J or blood pressure high mouse strain) mice were treated with LV control or LV with Oct-3/4-Sox-2-Klf-4 and evaluated 10 days post-infection. The blood pressure, cardiac function, vascular reactivity of small arteries, and EndMT inhibition were analyzed.
OSK overexpression induced partial EC reprogramming in vitro, and these cells had lower migratory capability. OSK treatment of BPH/2J mice reduced blood pressure and resistance arteries hypercontractility, via the attenuation of endothelial-to-mesenchymal transition and elastin breaks. EGFP was detected in vivo in the prefrontal cortex. OSK-treated hypertensive human aortic ECs showed high eNOS activation and NO production, with low reactive oxygen species (ROS) formation. Single-cell RNA analysis showed that OSK alleviated EC senescence and EndMT, restoring their phenotypes in human aortic ECs from patients with hypertension.
Overall, these data indicate that OSK treatment and EC reprogramming can decrease blood pressure and reverse hypertension-induced vascular damage.
小动脉重塑和内皮功能障碍是高血压的特征。有证据支持心血管疾病与内皮-间充质转化(EndMT)之间可能存在因果关系,EndMT是一种细胞转分化过程,其中内皮细胞(ECs)部分丧失其特性并获得间充质表型。EC重编程是再生医学中一种创新策略,用于预防心血管疾病引起的有害影响。
通过Oct-3/4-Sox-2-Klf-4(OSK)转录因子的过表达对ECs进行部分重编程,我们旨在使高血压患者的ECs恢复到年轻表型。原代ECs用含有特异性EC启动子Cdh5(钙黏蛋白-5)和报告基因EGFP(增强型绿色荧光蛋白)的慢病毒载体(LVs)感染,载体为空载体(LV对照)或携带Oct-3/4-Sox-2-Klf-4的LV。共聚焦显微镜和蛋白质免疫印迹分析用于确认OSK的过表达。评估细胞迁移、衰老和凋亡。对正常血压患者和高血压患者的人主动脉ECs进行OSK处理后,分析内皮型一氧化氮合酶(eNOS)、一氧化氮(NO)和基因谱。对雄性和雌性正常血压(BPN/3J或血压正常小鼠品系)和高血压(BPH/2J或血压高小鼠品系)小鼠用LV对照或携带Oct-3/4-Sox-2-Klf-4的LV进行处理,并在感染后10天进行评估。分析血压、心脏功能、小动脉的血管反应性和EndMT抑制情况。
OSK过表达在体外诱导了ECs的部分重编程,这些细胞具有较低的迁移能力。对BPH/2J小鼠进行OSK处理可降低血压和阻力动脉的过度收缩,这是通过减弱内皮-间充质转化和弹性蛋白断裂实现的。在体内前额叶皮质中检测到了EGFP。经OSK处理的高血压人主动脉ECs表现出高eNOS激活和NO产生,活性氧(ROS)形成较少。单细胞RNA分析表明,OSK减轻了ECs衰老和EndMT,使高血压患者的人主动脉ECs恢复其表型。
总体而言,这些数据表明OSK处理和EC重编程可降低血压并逆转高血压引起的血管损伤。